Positive Five-Year Outcomes Seen for Nivolumab in Resectable Lung Cancer
WEDNESDAY, Feb. 15, 2023 -- For patients with resectable non-small cell lung cancer (NSCLC), neoadjuvant nivolumab is associated with positive five-year outcomes, according to a study published online Feb. 15 in Clinical Cancer Research.
Samuel...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Lung Cancer | Neoadjuvant Therapy | Non-Small Cell Lung Cancer | Pharmaceuticals | Study